Analysts Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $13.63

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Free Report) has been given a consensus rating of “Buy” by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued ratings on the stock in […]

Leave a Reply

Your email address will not be published.

Previous post Analysts Set The Sage Group plc (LON:SGE) Target Price at GBX 930
Next post NVIDIA Co. (NASDAQ:NVDA) Given Average Recommendation of “Moderate Buy” by Brokerages